177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

NCT04315246 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business priorities

Conditions

Leptomeningeal Metastasis
Solid Tumor, Adult

Interventions

BIOLOGICAL: radiolabeled DPTA-omburtamab

Sponsor

Y-mAbs Therapeutics